<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MDVN</title>
	<atom:link href="http://www.stockbloghub.com/tag/mdvn/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DNDN) Dendreon&#8217;s Provenge Showing Bleak Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847</link>
		<comments>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847#comments</comments>
		<pubDate>Mon, 05 Mar 2012 15:19:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=93847</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate loss of 31 cents and year-ago loss of 60 cents per share. Full-year loss of $1.68 per share (excluding special items but including stock-based compensation expense) were narrower than the Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss of $3.07 per share. Total revenue in the reported quarter climbed to $202.1 million from $25.0 million in the comparable quarter of 2010. We note, however, that revenue in the reported quarter included one time royalty revenue of $125 million related to sale of its royalty interest in Merck, Inc.’s (MRK) hepatitis C product Victrelis. Excluding this one-time revenue, Dendreon ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618</link>
		<comments>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618#comments</comments>
		<pubDate>Mon, 07 Nov 2011 15:14:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86618</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) shares received a major boost recently with the company and its partner, Astellas, reporting impressive data on MDV3100 from a pre-specified interim analysis of a phase III study, AFFIRM. The Independent Data Monitoring Committee (IDMC) recommended that MDV3100&#8242;s risk-to-benefit ratio was favorable enough to stop the study. Medivation and Astellas intend to conduct a pre-NDA meeting with the FDA in early 2012. We believe the companies will file for regulatory approval of MDV3100 soon thereafter and expect MDV3100 to hit the market in 2013. Based on the data that we have seen so far, we believe MDV3100 has blockbuster potential and will be a game-changer for Medivation. We are upgrading Medivation to Outperform based on the improved prospects of the company. MEDIVATION INC (MDVN): Free Stock Analysis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/07/mdvn-medivation-incorporated-bull-of-the-day/86618/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Loss Narrows</title>
		<link>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549</link>
		<comments>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549#comments</comments>
		<pubDate>Sun, 06 Nov 2011 19:55:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86549</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance of its prostate cancer vaccine Provenge in the quarter. Loss was, however, much wider than the year-ago loss of 54 cents per share. Quarterly Details Total revenue in the reported quarter climbed to $64.3 million (including rebates and charge-backs) from $20.2 million in the comparable quarter of 2010. The jump was attributable to the higher Provenge revenue in the current quarter versus low Provenge sales in the third quarter of 2010 as it was only the second quarter of its launch. Revenues were also above the Zacks Consensus Estimate of $63 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376</link>
		<comments>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:42:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82376</guid>
		<description><![CDATA[We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results. Dendreon Corporation reported weaker-than-expected second quarter 2011 sales of $49.6 million of its potential blockbuster prostate cancer vaccine Provenge, though up from prior quarters. Revenues also disappointed the Zacks Consensus Estimate of $59 million in the second quarter. Management surmised that though the physician interest in the vaccine remains solid, its uptake will be slow and gradual. Subsequently, the company withdrew its revenue guidance for the drug, sending its share price down sharply. Provenge is the first product in a new therapeutic class known as &#8220;active cellular immunotherapies.&#8221; We believe that Provenge is capable of changing the paradigm of cancer care dramatically. Provenge is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/dndn-dendreon-analyst-maintains-neutral-on-shares/82376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Medicare to Cover Dendreon&#8217;s Provenge</title>
		<link>http://www.stockbloghub.com/2011/07/01/dndn-medicare-to-cover-dendreons-provenge/78214</link>
		<comments>http://www.stockbloghub.com/2011/07/01/dndn-medicare-to-cover-dendreons-provenge/78214#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:36:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78214</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) has of late been announcing significant milestones, related to its potential blockbuster cancer vaccine Provenge. Most recently, the company announced that the Centers for Medicare and Medicaid Services (CMS) has agreed to fully reimburse Provenge, an expensive vaccine. CMS is a federal agency that administers the Medicare and Medicaid programs, which provide health care coverage to millions of people in the US. The agency has issued a final National Coverage Decision (NCD) for Provenge which will require Medicare contractors to cover the use of Provenge for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer which is consistent with its label. The agency has also issued specific guidelines to local Medicare Administrative Contractors (MACs) to pay for on-label use of Provenge. Provenge is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/dndn-medicare-to-cover-dendreons-provenge/78214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Gets FDA Clearance on Second Facility</title>
		<link>http://www.stockbloghub.com/2011/07/01/dndn-dendreon-gets-fda-clearance-on-second-facility/78151</link>
		<comments>http://www.stockbloghub.com/2011/07/01/dndn-dendreon-gets-fda-clearance-on-second-facility/78151#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:36:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78151</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) recently received clearance from the U.S. Food and Drug Administration (FDA) to expand manufacturing facility for its cancer vaccine Provenge, in the U.S. The company’s Los Angeles facility can now be operational with 36 workstations. These facilities will be brought online in a staged manner. Earlier, in March 2011, Dendreon’s New Jersey facility received FDA clearance. The facility has 48 workstations, some of which are already operational. The LA and NJ facilities, geared for manufacturing Provenge, now total 84. We believe the expanding manufacturing capacity will significantly increase the availability of Provenge which will help Dendreon to meet pent up demand for the vaccine. The company is also building additional capacity in Atlanta for which the FDA is expected to give its decision in August 2011. All ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/dndn-dendreon-gets-fda-clearance-on-second-facility/78151/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BOBE) Company News for May 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828</link>
		<comments>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828#comments</comments>
		<pubDate>Wed, 11 May 2011 16:16:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Restaurants]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Bob Evans Farms Inc.]]></category>
		<category><![CDATA[BOBE]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Chesapeake Utilities Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Cosan Limited]]></category>
		<category><![CDATA[CPK]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CZZ]]></category>
		<category><![CDATA[Dean Foods Company]]></category>
		<category><![CDATA[DF]]></category>
		<category><![CDATA[DHX]]></category>
		<category><![CDATA[Dice Holdings Inc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPK]]></category>
		<category><![CDATA[Graphic Packaging Holding Company]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[NGLS]]></category>
		<category><![CDATA[PANL]]></category>
		<category><![CDATA[Targa Resources Partners LP]]></category>
		<category><![CDATA[Universal Display Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73828</guid>
		<description><![CDATA[•    Microsoft Corp. (NASDAQ:MSFT) will purchase internet communications leader Skype from the investor consortium led by Silver Lake. The deal which is worth $8.5 billion in cash has been approved by the boards of directors of both companies •    Dean Foods (NYSE:DF) reported Q1 EPS of $0.14, surpassing the Zacks Consensus Estimate of $0.06 per share •    Medical-device maker Boston Scientific Corporation (NYSE:BSX) announced that Ray Elliott would retire as president and CEO at the end of the year •    Shares of online technology-jobs sites operator DICE HOLDINGS, INC. (NYSE:DHX) dropped 5.5% a day after the company revealed that “certain stockholders” would sell 8 million shares. •    Share prices of MannKind Corp.(NASDAQ:MNKD) plunged 12.3% a day after the biotechnology firm  reported a first-quarter loss exceeding expectations •    Late on Monday, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/11/bobe-company-news-for-may-11-2011-corporate-summary/73828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Earns FDA Approval for Cancer Drug</title>
		<link>http://www.stockbloghub.com/2011/05/09/jnj-johnson-and-johnson-earns-fda-approval-for-cancer-drug/73485</link>
		<comments>http://www.stockbloghub.com/2011/05/09/jnj-johnson-and-johnson-earns-fda-approval-for-cancer-drug/73485#comments</comments>
		<pubDate>Mon, 09 May 2011 14:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73485</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) recently announced US Food and Drug Administration (FDA) approval for its prostate cancer therapy, Zytiga (abiraterone acetate). Zytiga, an oral, once-daily medication, gained approval for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in treatment-experienced patients whose chemotherapy contained docetaxel. Phase III data on Zytiga showed a significant increase in median survival in patients treated with Zytiga and prednisone compared to patients treated with placebo and prednisone. A 35% reduction in the risk of death (14.8 months vs. 10.9 months) and a 3.9 month difference in median survival was observed in patients treated with Zytiga and prednisone compared to patients on placebo plus prednisone. Though there is no direct competition at present, Zytiga may one day compete with Dendreon Corporation’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/jnj-johnson-and-johnson-earns-fda-approval-for-cancer-drug/73485/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MNKD) Why Phase II is the Sweet Spot for Biotech Investing</title>
		<link>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385#comments</comments>
		<pubDate>Wed, 13 Apr 2011 16:23:10 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEL-SCI Corporation]]></category>
		<category><![CDATA[CVM]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Electro-optical Sciences Inc]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[MELA]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71385</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U’s Healthcare Expert Wednesday, April 13, 2011: Issue #1490 I recently received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phase II trials. Would Rory McIlroy have liked a do-over on Sunday at Augusta? Phase II trials are my favorite time to get involved in a biotech company. I’ll explain why in a moment. But first, a quick review of the phases of clinical trials… The Three Distinct Phases of Clinical Trials Before a new, experimental drug is tried in humans, it’s put to work in test tubes and then animals. Once it’s ready for human trials, it’s tested in three distinct phases. The Phase I trial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mnkd-why-phase-ii-is-the-sweet-spot-for-biotech-investing/71385/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Learns Medicare May Pay for Provenge Prostate Cancer Vaccine</title>
		<link>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376</link>
		<comments>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376#comments</comments>
		<pubDate>Mon, 11 Apr 2011 02:58:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70376</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) received a huge boost today when the Centers for Medicare and Medicaid Services (CMS) proposed to pay for its lead prostate cancer vaccine Provenge. Provenge was approved in the US in April last year and is marketed since May 2010. It is currently reimbursed by all 15 local Medicare contractors. CMS issued the proposed decision memo for Dendreon’s potential blockbuster vaccine, Provenge, after conducting a scientific review of the evidence provided. The agency believes there is enough evidence to justify reimbursement for the approved label of the vaccine. CMS believes Provenge leads to improvement in health outcomes for men with advanced, castrate-resistant prostate cancer (CRPC) and is clinically necessary, as per CMS. The agency did not propose to cover off-label use of the vaccine at the national ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/dndn-dendreon-learns-medicare-may-pay-for-provenge-prostate-cancer-vaccine/70376/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480</link>
		<comments>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480#comments</comments>
		<pubDate>Fri, 01 Apr 2011 16:17:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Nidec Corporation]]></category>
		<category><![CDATA[NJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70480</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $39.00 following the announcement of fourth quarter and full year 2010 financial results. Dendreon’s fourth quarter 2010 loss of 61 cents per share (excluding loss on debt conversion) was wider than the Zacks Consensus Estimate of a loss of 48 cents per share and the year-ago loss of 31 cents per share (excluding gain for warrant revaluation). On a reported basis (including special items), the company lost 64 cents per share in the fourth quarter as against a loss of 28 cents per share in the year-ago quarter. The wider loss was attributable to higher operating expenses as the company is working on expanding its facilities to market Provenge. Dendreon’s lead product is prostate cancer ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/01/dndn-dendreon-analyst-maintains-neutral-rating-on-shares/70480/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Analyst Reiterates Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/23/mdvn-medivation-analyst-reiterates-neutral-rating/49064</link>
		<comments>http://www.stockbloghub.com/2010/08/23/mdvn-medivation-analyst-reiterates-neutral-rating/49064#comments</comments>
		<pubDate>Tue, 24 Aug 2010 00:00:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49064</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on biopharmaceutical company Medivation Inc. (MDVN). Medivation, which currently does not have any marketed product in its portfolio, focuses on the development of novel small molecule drugs for the treatment of serious diseases for which there are limited treatment options. The company’s lead pipeline candidates are Dimebon, which is being developed for the treatment of Alzheimer’s and Huntington’s diseases, and MDV3100, which is being developed for the treatment of castration-resistant prostate cancer. While Dimebon is being partnered with Pfizer (PFE), Medivation has an agreement with Japanese company, Astellas Pharma, for the development and commercialization of MDV3100. We view both these collaborative agreements as favorable for the company. Not only have these collaborations brought in cash for Medivation, they have also provided the company with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/23/mdvn-medivation-analyst-reiterates-neutral-rating/49064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation 2010 Second Quarter Earnings Narrow Loss</title>
		<link>http://www.stockbloghub.com/2010/08/11/mdvn-medivation-2010-second-quarter-earnings-narrow-loss/47459</link>
		<comments>http://www.stockbloghub.com/2010/08/11/mdvn-medivation-2010-second-quarter-earnings-narrow-loss/47459#comments</comments>
		<pubDate>Wed, 11 Aug 2010 14:52:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47459</guid>
		<description><![CDATA[Medivation Inc. (MDVN) reported a loss of 21 cents per share in the second quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 29 cents. Lower expenses led to the narrower loss. Revenues for the quarter were $15.8 million, well below the Zacks Consensus Estimate of $17 million. Revenues were $16.3 million in the year-ago period. Quarter in Detail Revenues consisted of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008 and $110 million received from Astellas in late 2009. The upfront payments are being recognized on a straight-line basis while the Pfizer payment will be recognized through the second quarter of 2013, the Astellas payment will be recognized through the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/mdvn-medivation-2010-second-quarter-earnings-narrow-loss/47459/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Quarterly Report Shows Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433</link>
		<comments>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433#comments</comments>
		<pubDate>Mon, 17 May 2010 22:09:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37433</guid>
		<description><![CDATA[Medivation Inc. (MDVN) reported a loss of 51 cents per share in the first quarter of 2010, exceeding the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 19 cents. Lower revenues and higher expenses led to the higher loss. Revenues for the quarter were $15.7 million, consisting of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008 and $110 million received from Astellas in late 2009. The upfront payments are being recognized on a straight-line basis – while the Pfizer payment will be recognized through the second quarter of 2013, the Astellas payment will be recognized through the fourth quarter of 2014. Revenues were $16.3 million in the year-ago period. Operating expenses grew from $22.1 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/mdvn-medivation-quarterly-report-shows-wider-loss/37433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Announces Workforce Reductions</title>
		<link>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520</link>
		<comments>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520#comments</comments>
		<pubDate>Thu, 01 Apr 2010 14:59:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32520</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and development activities related to dimebon and MDV3100. Medivation also announced the departure of its senior vice president of clinical development and the vice president of commercial development. The company said that it is no longer looking for a new Chief Financial Officer (CFO) as this post will be filled by the current Chief Business Officer (CBO). Medivation’s workforce reduction announcement comes on the heels of disappointing phase III results reported earlier this month on its lead pipeline candidate, dimebon. Dimebon, which is being developed for Alzheimer’s disease in collaboration with Pfizer, Inc. (PFE), failed to achieve both its primary and secondary endpoints in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/mdvn-medivation-announces-workforce-reductions/32520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Reports Wider Fourth Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766</link>
		<comments>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:50:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30766</guid>
		<description><![CDATA[Medivation Inc. (MDVN) reported dismal results in the fourth quarter of 2009 with net loss coming in at 78 cents per share, wider than the Zacks Consensus Estimate of a net loss of 57 cents and the year-ago net loss of 26 cents. Despite full year revenues increasing to $69.3 million, net loss increased due to higher operating expenses. Net loss for 2009 came in at $1.71, wider than the Zacks Consensus Estimate of a net loss of $1.42. Full year revenues consisted of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in Oct 2008 and $110 million received from Astellas in the fourth quarter of 2009. While the upfront payment from Pfizer is being recognized on a straight-line basis through the first quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/mdvn-medivation-reports-wider-fourth-quarter-loss/30766/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Shares Fall on Alzheimer&#8217;s Phase III Data</title>
		<link>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721</link>
		<comments>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:33:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29721</guid>
		<description><![CDATA[Medivation, Inc. (MDVN) shares fell 67% following the release of disappointing phase III results on lead pipeline candidate dimebon. The company, along with partner Pfizer, Inc. (PFE), suffered a huge setback when dimebon failed to achieve both its primary and secondary endpoints in the CONNECTION study. The phase III, multi-national, double-blind, placebo-controlled safety and efficacy trial was conducted across 63 sites in North America, Europe, and South America with 598 patients suffering from mild-to-moderate Alzheimer’s disease. Results showed that dimebon failed to achieve a statistically significant improvement over placebo. These results are extremely disappointing for both Medivation and Pfizer. Pfizer has already invested a significant amount of money towards the development of the candidate. The company made an upfront payment of $225 million to Medivation under the collaboration agreement and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/04/mdvn-medivation-shares-fall-on-alzheimers-phase-iii-data/29721/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($JPM) JP Morgan Healthcare Conference in San Francisco</title>
		<link>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897</link>
		<comments>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897#comments</comments>
		<pubDate>Wed, 13 Jan 2010 23:58:21 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[WBMD]]></category>
		<category><![CDATA[WebMD Health Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24897</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 13, 2010: Issue #1174 Cautiously optimistic. Very cautiously optimistic. That’s how I’d describe the overall mood at this year’s JP Morgan Healthcare Conference in San Francisco. While folks are certainly in a better frame of mind than this time last year (when it seemed like we were in the middle of financial Armageddon), they’re still a bit gun-shy. But with the huge stock market rally and partnership/financing deals available again, the tone is more upbeat. As one banker said, “money is flowing into the market again.” These days, the conference is a major event and has become increasingly difficult to get into. Luckily, I’ve got the right credentials to get inside (without having to resort to a White House-style gatecrash) and give you ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/jpm-jp-morgan-healthcare-conference-in-san-francisco/24897/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation Incorporated Starts New Alzheimer&#8217;s Trials</title>
		<link>http://www.stockbloghub.com/2009/11/18/mdvn-medivation-incorporated-starts-new-alzheimers-trials/20884</link>
		<comments>http://www.stockbloghub.com/2009/11/18/mdvn-medivation-incorporated-starts-new-alzheimers-trials/20884#comments</comments>
		<pubDate>Wed, 18 Nov 2009 22:44:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20884</guid>
		<description><![CDATA[Earlier this month, Medivation, Inc. (MDVN) and Pfizer, Inc. (PFE) initiated two phase III studies, CONTACT and CONSTELLATION, with Dimebon in patients with moderate-to-severe Alzheimer&#8217;s disease (AD). Dimebon is being developed in collaboration with Pfizer for the treatment of Alzheimer’s and Huntington diseases. The CONTACT study will assess the potential benefits of adding Dimebon to ongoing treatment with Pfizer’s Aricept on neuropsychiatric symptoms and activities of daily living. Meanwhile, the CONSTELLATION study will evaluate the effects of adding Dimebon to Forest Lab’s (FRX) Namenda, another standard of care, on cognition, memory and activities of daily living. Preclinical studies indicate that Dimebon has the potential to protect brain cells from damage and enhance brain cell survival, by stabilizing and improving mitochondrial function. Dimebon’s mechanism is distinct from currently available Alzheimer’s medications. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/mdvn-medivation-incorporated-starts-new-alzheimers-trials/20884/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Medivation&#8217;s Earnings Report Lags Expectations</title>
		<link>http://www.stockbloghub.com/2009/11/08/mdvn-medivations-earnings-report-lags-expectations/19868</link>
		<comments>http://www.stockbloghub.com/2009/11/08/mdvn-medivations-earnings-report-lags-expectations/19868#comments</comments>
		<pubDate>Mon, 09 Nov 2009 02:53:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19868</guid>
		<description><![CDATA[Medivation Inc. (MDVN) has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. However, net loss declined from the year-ago loss of 68 cents. Revenue for the quarter was $16.3 million, consisting of partial recognition of the non-refundable upfront payment of $225 million received from Pfizer (PFE) in October 2008. The upfront payment is being recognized on a straight-line basis through the first quarter of 2012. Revenues were nil in the year-ago period. Operating expenses grew from $20.6 million in the year-ago period to $27.6 million in the quarter. Research and development expenses increased to $21.5 million as a result of greater clinical trials expenses which were partially offset by a cost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/08/mdvn-medivations-earnings-report-lags-expectations/19868/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDVN) Three Ways to Stop Making Emotional Investment Decisions</title>
		<link>http://www.stockbloghub.com/2009/09/02/mdvn-three-ways-to-stop-making-emotional-investment-decisions/14261</link>
		<comments>http://www.stockbloghub.com/2009/09/02/mdvn-three-ways-to-stop-making-emotional-investment-decisions/14261#comments</comments>
		<pubDate>Thu, 03 Sep 2009 01:42:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14261</guid>
		<description><![CDATA[by Marc Lichtenfeld, Advisory Panelist “You think they’re your friends, but they’re not your friends.” This was the frequent refrain from a landlord I had while in college. He was warning us on the danger of throwing parties and inviting people who we considered friends, but would think nothing of trashing the place. I guess it’s not surprising that renting his house to college kids made him a little paranoid. He often showed up at random times to make sure there was no revelry taking place. Once, he chased away some of my buddies as we were watching “Monday Night Football” (I guess the keg in the corner didn’t help our argument). This no-nonsense, unattached attitude is the perfect way to approach the stock market and your investments. After all, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/mdvn-three-ways-to-stop-making-emotional-investment-decisions/14261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

